help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. 5, 596-607, May 2008; doi:10.1634/theoncologist.2007-0219
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spaepen, E.
Right arrow Articles by Annemans, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spaepen, E.
Right arrow Articles by Annemans, L.

Symptom Management and Supportive Care

Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals

Erik Spaepena, Nadia Demarteaua, Simon Van Belleb, Lieven Annemansb

aIMS Health, Brussels, Belgium; bGhent University, Ghent, Belgium

Key Words. Anemia • Cancer • Chemotherapy • Economic • Erythropoiesis-stimulating agents • Transfusion

Correspondence: Erik Spaepen, M.Sc., IMS Health, Rue de Crayer 6, 1000, Brussels, Belgium. Telephone: 32-2-627-3211; Fax: 32-2-627-3334; e-mail: ESpaepen{at}be.imshealth.com; Erik219{at}yahoo.com

Received November 7, 2007; accepted for publication March 28, 2008.

Disclosure: L.A. has performed contract work for Ghent University. N.D. has performed contract work for IMS Health. E.S. is an employee of IMS Health and has worked as a contractor for Amgen regarding erythropoietins. The study was performed by IMS for Amgen and funded by an educational grant from Amgen. The authors acknowledge that E.S. and N.D. received payment from Amgen for writing the article.

Background. Erythropoiesis-stimulating agents (ESAs) are used in chemotherapy-induced anemia (CIA) with the goal of improving quality of life and preventing RBC transfusions. This retrospective database study compared the three currently available ESAs, epoetin alfa (EPO-A), epoetin beta (EPO-B), and darbepoetin alfa (DARB), regarding costs and outcomes.

Methods. Data were obtained from a Belgian longitudinal database, including medical and financial data on cancer patients receiving chemotherapy and ESAs, submitted by 46 Belgian hospitals. Propensity score matching was applied to correct for selection bias. The main effectiveness parameter was defined as transfusion- and anemia-readmission-free survival (TA-free survival) at 3 months. Costs were analyzed taking the health care payer perspective.

Results. Including 1,584 EPO-A, 380 EPO-B, and 429 DARB propensity-matched patients, TA-free survival rates were similar for the three groups (DARB, 84.37%; EPO-A, 84.60%; EPO-B, 84.94%). Overall inpatient costs were {euro}16,949 ± {euro}1,025, {euro}19,472 ± {euro}901, and {euro}19,295 ± {euro}1,048 for DARB, EPO-A, and EPO-B, respectively (DARB versus EPO-A, p < .0001 and DARB versus EPO-B, p = .008). Anemia-associated costs were {euro}3,051 ± {euro}218 in the DARB group, compared with {euro}3,995 ± {euro}144 for EPO-A (p < .0001) and {euro}3,752 ± {euro}229 for EPO-B (p = .0132).

Conclusion. To our knowledge, this is the first real-life matched retrospective study comparing ESAs with regard to both costs and effects. For similar patient profiles, the patients in the DARB group consumed the smallest amounts of ESAs, with similar clinical outcomes. These data therefore suggest a greater efficiency of DARB in the treatment of CIA.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.